It has been demonstrated that MTAP deficiency, leading to MTA accumulation, offers a therapeutic window by creating a hypomorphic PRMT5 state that selectively sensitizes cancer cells to PRMT5 inhibition [112]. This evidence concerns the gene PRMT5 and cancer.